Incidence of acute serious bacterial infections one year [clinicaltrials_resource:aba7e7138fc403b8243a32287e89ffc7]
Acute serious bacterial infections are defined in The FDA(CBER) Guidance for industry for studies of IGIV to support marketing of IGIV as replacement therapy for primary humoral immunodeficiency (June, 2008).
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Incidence of acute serious bacterial infections one year [clinicaltrials_resource:aba7e7138fc403b8243a32287e89ffc7]
Acute serious bacterial infections are defined in The FDA(CBER) Guidance for industry for studies of IGIV to support marketing of IGIV as replacement therapy for primary humoral immunodeficiency (June, 2008).
Bio2RDF identifier
aba7e7138fc403b8243a32287e89ffc7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:aba7e7138fc403b8243a32287e89ffc7
measure [clinicaltrials_vocabulary:measure]
Incidence of acute serious bacterial infections
time frame [clinicaltrials_vocabulary:time-frame]
description
Acute serious bacterial infect ...... immunodeficiency (June, 2008).
identifier
clinicaltrials_resource:aba7e7138fc403b8243a32287e89ffc7
title
Incidence of acute serious bacterial infections one year
@en
type
label
Incidence of acute serious bac ...... 7e7138fc403b8243a32287e89ffc7]
@en